Oncologic outcomes following robot-assisted radical cystectomy with minimum 5-year follow-up: the Roswell Park cancer institute experience.
BACKGROUND
Long-term oncologic outcomes following robot-assisted radical cystectomy (RARC) remain scarce.


OBJECTIVE
To report long-term oncologic outcomes following RARC at a single institution.


METHODS
Retrospective review of 99 patients who underwent RARC for urothelial carcinoma of bladder between 2005 and 2009.


METHODS
RARC was performed.


METHODS
Primary outcomes included recurrence-free survival (RFS), cancer-specific survival (CSS), and overall survival (OS), measured by the Kaplan-Meier method. The association between primary outcomes and perioperative and pathologic factors was assessed using a multivariable Cox proportional hazards model.


CONCLUSIONS
Fifty-one (52%) patients had stage pT3 or higher disease. Eight (8%) patients had positive margins and 30 (30%) had positive lymph nodes (LNs), with a median of 21 LNs removed. Median follow-up for patients alive was 74 mo. The 5-yr RFS, CSS, and OS rates were 52.5%, 67.8%, and 42.4%, respectively. Tumor stage, LN stage, and margin status were each significantly associated with RFS, CSS, and OS. On multivariable analysis, tumor and LN stage were independent predictors of RFS, CSS, and OS, while positive margin status and Charlson comorbidity index predicted worse OS and CSS. Adjuvant chemotherapy predicted RFS only. Retrospective design and lack of open comparison are main limitations of this study.


CONCLUSIONS
Long-term oncologic outcomes following RARC demonstrate RFS and CSS estimates similar to those reported in literature for open radical cystectomy. Randomized controlled trials can better define outcomes of any alternative technique.


RESULTS
Survival data 5 yr after RARC for bladder cancer demonstrate that survival outcomes are dependent on the same oncologic parameters as previously reported for open surgery.
Department of Urology, Roswell Park Cancer Institute, Buffalo, NY, USA.
Syed Johar
SJ
Raza
Department of Urology, Roswell Park Cancer Institute, Buffalo, NY, USA.
Ali
A
Al-Daghmin
Department of Urology, Roswell Park Cancer Institute, Buffalo, NY, USA.
Sharon
S
Zhuo
Department of Urology, Roswell Park Cancer Institute, Buffalo, NY, USA.
Zayn
Z
Mehboob
Department of Biostatistics, Roswell Park Cancer Institute, Buffalo, NY, USA.
Katy
K
Wang
Department of Biostatistics, Roswell Park Cancer Institute, Buffalo, NY, USA.
Gregory
G
Wilding
Department of Urology, Roswell Park Cancer Institute, Buffalo, NY, USA; Department of Cancer Genetics, Roswell Park Cancer Institute, Buffalo, NY, USA.
Eric
E
Kauffman
Department of Urology, Roswell Park Cancer Institute, Buffalo, NY, USA. Electronic address: khurshid.guru@roswellpark.org.
Khurshid A
KA
Guru
D000368:Aged; D002277:Carcinoma / Q000401:mortality / Q000556:secondary / Q000601:surgery*; D017024:Chemotherapy, Adjuvant; D015897:Comorbidity; D015653:Cystectomy / Q000009:adverse effects / Q000379:methods* / Q000401:mortality; D018450:Disease Progression; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D018365:Neoplasm, Residual; D009518:New York; D016016:Proportional Hazards Models; D012189:Retrospective Studies; D012307:Risk Factors; D065287:Robotic Surgical Procedures / Q000009:adverse effects / Q000379:methods* / Q000401:mortality; D013997:Time Factors; D016896:Treatment Outcome; D001749:Urinary Bladder Neoplasms / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D019459:Urothelium / Q000473:pathology / Q000601:surgery*
Long term; Oncologic Outcomes; Outcomes; Radical Cystectomy; Robot-assisted